{
    "clinical_study": {
        "@rank": "119225", 
        "arm_group": [
            {
                "arm_group_label": "MP-424(+RBV+IFN), Genotype1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "RBV+IFN, Genotype1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MP-424(+RBV+IFN), Genotype2", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients\n      with genotype 1/2 hepatitis C, who are treatment-na\u00efve  or have received  its treatment\n      before."
        }, 
        "brief_title": "Efficacy and Safety of MP-424, Interferon Beta (IFN Beta), and Ribavirin(RBV) in Treatment-Na\u00efve or Having Received Interferon Based Therapy With Chronic Hepatitis C (CHC)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C(CHC)", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genotype 1 or 2, chronic hepatitis C, with depression(including the past)\n\n          -  treatment-na\u00efve or patient who have ever had previous treatment\n\n          -  Able and willing to follow contraception requirements\n\n        Exclusion Criteria:\n\n          -  Cirrhosis of the liver or hepatic failure\n\n          -  Hepatitis B surface antigen-positive or HIV antibodies-positive\n\n          -  History of, or concurrent hepatocellular carcinoma\n\n          -  History of, or concurrent serious depression, schizophrenia,; or suicide attempt in\n             the past\n\n          -  Pregnant, lactating, or suspected pregnant patients, or male patients whose female\n             partner is pregnant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 13, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01753570", 
            "org_study_id": "G060-F1"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "MP-424(+RBV+IFN), Genotype1", 
                    "MP-424(+RBV+IFN), Genotype2"
                ], 
                "description": "MP-424: 750mg every 8 hours (q8h) for 12 weeks", 
                "intervention_name": "MP-424", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MP-424(+RBV+IFN), Genotype1", 
                    "RBV+IFN, Genotype1", 
                    "MP-424(+RBV+IFN), Genotype2"
                ], 
                "description": "RBV: 600 - 1000 mg/day based on body weight for 48 weeks", 
                "intervention_name": "RBV", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "MP-424(+RBV+IFN), Genotype1", 
                    "RBV+IFN, Genotype1", 
                    "MP-424(+RBV+IFN), Genotype2"
                ], 
                "description": "IFN: 600 MIU/day, 6 days/week for initial 4 weeks following to 3 days/week", 
                "intervention_name": "IFN beta", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-beta", 
                "Interferons"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Feron", 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kawasaki City", 
                    "country": "Japan", 
                    "state": "Takatsu-ku", 
                    "zip": "213-8587"
                }, 
                "name": "Toranomon Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 3 Study of MP-424 in Combination With IFN Beta and RBV, in Subjects With Genotype 1/2 Hepatitis C, Who Are Treatment-Na\u00efve or Have Received Interferon Based Therapy", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": {
            "affiliation": "Mitsubishi Tanabe Pharma Corporation", 
            "last_name": "Kazuoki Kondo, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Undetectable HCV (Hepatitis C Virus) RNA (Ribonucleic Acid) at 24 weeks after completion of drug administration (SVR, sustained viral response)", 
            "safety_issue": "No", 
            "time_frame": "72 weeks(Genotype 1 groups), 48 weeks(Genotype 2 group)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01753570"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Undetectable HCV RNA at 4 weeks after beginning  of drug administration (RVR, rapid viral response)", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "Undetectable HCV RNA at completion of drug administration (ETR, end-of-treatment response)", 
                "safety_issue": "No", 
                "time_frame": "24 weeks(Genotype 1 groups), 24 weeks(Genotype 2 group)"
            }, 
            {
                "measure": "Undetectable HCV RNA at 12 weeks after completion of drug administration", 
                "safety_issue": "No", 
                "time_frame": "60 weeks(Genotype 1 groups), 36 weeks(Genotype 2 group)"
            }, 
            {
                "measure": "Transition of serum HCV RNA levels", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks after completion of drug administration"
            }, 
            {
                "measure": "Viral sequencing at the NS-3 protease region of HCV virus", 
                "safety_issue": "No", 
                "time_frame": "From baseline to 24 weeks after completion of drug administration"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Toray Industries, Inc", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}